Gestational Trophoblastic Disease Market, Global Outlook and Forecast 2023-2029

Report ID: MMG194238 | Category: Medical Devices & Consumables | Pages: 68 | Format: PDF | Published Date: September 04,2023

Request Sample Enquiry before buying Ask For Discount

Single User-$3250.00 Multi User-$4225.00

Report Description
View Table of Contents

Report Summary

Gestational trophoblastic disease (GTD) is a group of rare diseases in which abnormal trophoblast cells grow inside the uterus after conception. In gestational trophoblastic disease (GTD), a tumor develops inside the uterus from tissue that forms after conception (the joining of sperm and egg).
This report aims to provide a comprehensive presentation of the global market for Gestational Trophoblastic Disease, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gestational Trophoblastic Disease. This report contains market size and forecasts of Gestational Trophoblastic Disease in global, including the following market information:
Global Gestational Trophoblastic Disease Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Gestational Trophoblastic Disease market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Chemotherapy Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Gestational Trophoblastic Disease include Bristol Myers Squibb, Antares Pharma, Novartis AG, Accord Healthcare Limited, Eli Lilly and Company, Sanofi, Bayer AG, Amgen and Merck KGaA, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Gestational Trophoblastic Disease companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Gestational Trophoblastic Disease Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Gestational Trophoblastic Disease Market Segment Percentages, by Type, 2022 (%)
    Chemotherapy
    Surgery
    Radiation Therapy
    Others
Global Gestational Trophoblastic Disease Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Gestational Trophoblastic Disease Market Segment Percentages, by Application, 2022 (%)
    Hospitals
    Clinics
    Cancer Research Institutes
    Others
Global Gestational Trophoblastic Disease Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Gestational Trophoblastic Disease Market Segment Percentages, By Region and Country, 2022 (%)
    North America
        US
        Canada
        Mexico
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
        Nordic Countries
        Benelux
        Rest of Europe
    Asia
        China
        Japan
        South Korea
        Southeast Asia
        India
        Rest of Asia
    South America
        Brazil
        Argentina
        Rest of South America
    Middle East & Africa
        Turkey
        Israel
        Saudi Arabia
        UAE
        Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Gestational Trophoblastic Disease revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Gestational Trophoblastic Disease revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
    Bristol Myers Squibb
    Antares Pharma
    Novartis AG
    Accord Healthcare Limited
    Eli Lilly and Company
    Sanofi
    Bayer AG
    Amgen
    Merck KGaA
    Teva Pharmaceuticals
    B.P Pharma
Outline of Major Chapters:
Chapter 1: Introduces the definition of Gestational Trophoblastic Disease, market overview.
Chapter 2: Global Gestational Trophoblastic Disease market size in revenue.
Chapter 3: Detailed analysis of Gestational Trophoblastic Disease company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Gestational Trophoblastic Disease in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

1 Introduction to Research & Analysis Reports
    1.1 Gestational Trophoblastic Disease Market Definition
    1.2 Market Segments
        1.2.1 Market by Type
        1.2.2 Market by Application
    1.3 Global Gestational Trophoblastic Disease Market Overview
    1.4 Features & Benefits of This Report
    1.5 Methodology & Sources of Information
        1.5.1 Research Methodology
        1.5.2 Research Process
        1.5.3 Base Year
        1.5.4 Report Assumptions & Caveats
2 Global Gestational Trophoblastic Disease Overall Market Size
    2.1 Global Gestational Trophoblastic Disease Market Size: 2022 VS 2029
    2.2 Global Gestational Trophoblastic Disease Market Size, Prospects & Forecasts: 2018-2029
    2.3 Key Market Trends, Opportunity, Drivers and Restraints
        2.3.1 Market Opportunities & Trends
        2.3.2 Market Drivers
        2.3.3 Market Restraints
3 Company Landscape
    3.1 Top Gestational Trophoblastic Disease Players in Global Market
    3.2 Top Global Gestational Trophoblastic Disease Companies Ranked by Revenue
    3.3 Global Gestational Trophoblastic Disease Revenue by Companies
    3.4 Top 3 and Top 5 Gestational Trophoblastic Disease Companies in Global Market, by Revenue in 2022
    3.5 Global Companies Gestational Trophoblastic Disease Product Type
    3.6 Tier 1, Tier 2 and Tier 3 Gestational Trophoblastic Disease Players in Global Market
        3.6.1 List of Global Tier 1 Gestational Trophoblastic Disease Companies
        3.6.2 List of Global Tier 2 and Tier 3 Gestational Trophoblastic Disease Companies
4 Market Sights by Product
    4.1 Overview
        4.1.1 By Type - Global Gestational Trophoblastic Disease Market Size Markets, 2022 & 2029
        4.1.2 Chemotherapy
        4.1.3 Surgery
        4.1.4 Radiation Therapy
        4.1.5 Others
    4.2 By Type - Global Gestational Trophoblastic Disease Revenue & Forecasts
        4.2.1 By Type - Global Gestational Trophoblastic Disease Revenue, 2018-2023
        4.2.2 By Type - Global Gestational Trophoblastic Disease Revenue, 2024-2029
        4.2.3 By Type - Global Gestational Trophoblastic Disease Revenue Market Share, 2018-2029
5 Sights by Application
    5.1 Overview
        5.1.1 By Application - Global Gestational Trophoblastic Disease Market Size, 2022 & 2029
        5.1.2 Hospitals
        5.1.3 Clinics
        5.1.4 Cancer Research Institutes
        5.1.5 Others
    5.2 By Application - Global Gestational Trophoblastic Disease Revenue & Forecasts
        5.2.1 By Application - Global Gestational Trophoblastic Disease Revenue, 2018-2023
        5.2.2 By Application - Global Gestational Trophoblastic Disease Revenue, 2024-2029
        5.2.3 By Application - Global Gestational Trophoblastic Disease Revenue Market Share, 2018-2029
6 Sights by Region
    6.1 By Region - Global Gestational Trophoblastic Disease Market Size, 2022 & 2029
    6.2 By Region - Global Gestational Trophoblastic Disease Revenue & Forecasts
        6.2.1 By Region - Global Gestational Trophoblastic Disease Revenue, 2018-2023
        6.2.2 By Region - Global Gestational Trophoblastic Disease Revenue, 2024-2029
        6.2.3 By Region - Global Gestational Trophoblastic Disease Revenue Market Share, 2018-2029
    6.3 North America
        6.3.1 By Country - North America Gestational Trophoblastic Disease Revenue, 2018-2029
        6.3.2 US Gestational Trophoblastic Disease Market Size, 2018-2029
        6.3.3 Canada Gestational Trophoblastic Disease Market Size, 2018-2029
        6.3.4 Mexico Gestational Trophoblastic Disease Market Size, 2018-2029
    6.4 Europe
        6.4.1 By Country - Europe Gestational Trophoblastic Disease Revenue, 2018-2029
        6.4.2 Germany Gestational Trophoblastic Disease Market Size, 2018-2029
        6.4.3 France Gestational Trophoblastic Disease Market Size, 2018-2029
        6.4.4 U.K. Gestational Trophoblastic Disease Market Size, 2018-2029
        6.4.5 Italy Gestational Trophoblastic Disease Market Size, 2018-2029
        6.4.6 Russia Gestational Trophoblastic Disease Market Size, 2018-2029
        6.4.7 Nordic Countries Gestational Trophoblastic Disease Market Size, 2018-2029
        6.4.8 Benelux Gestational Trophoblastic Disease Market Size, 2018-2029
    6.5 Asia
        6.5.1 By Region - Asia Gestational Trophoblastic Disease Revenue, 2018-2029
        6.5.2 China Gestational Trophoblastic Disease Market Size, 2018-2029
        6.5.3 Japan Gestational Trophoblastic Disease Market Size, 2018-2029
        6.5.4 South Korea Gestational Trophoblastic Disease Market Size, 2018-2029
        6.5.5 Southeast Asia Gestational Trophoblastic Disease Market Size, 2018-2029
        6.5.6 India Gestational Trophoblastic Disease Market Size, 2018-2029
    6.6 South America
        6.6.1 By Country - South America Gestational Trophoblastic Disease Revenue, 2018-2029
        6.6.2 Brazil Gestational Trophoblastic Disease Market Size, 2018-2029
        6.6.3 Argentina Gestational Trophoblastic Disease Market Size, 2018-2029
    6.7 Middle East & Africa
        6.7.1 By Country - Middle East & Africa Gestational Trophoblastic Disease Revenue, 2018-2029
        6.7.2 Turkey Gestational Trophoblastic Disease Market Size, 2018-2029
        6.7.3 Israel Gestational Trophoblastic Disease Market Size, 2018-2029
        6.7.4 Saudi Arabia Gestational Trophoblastic Disease Market Size, 2018-2029
        6.7.5 UAE Gestational Trophoblastic Disease Market Size, 2018-2029
7 Gestational Trophoblastic Disease Companies Profiles
    7.1 Bristol Myers Squibb
        7.1.1 Bristol Myers Squibb Company Summary
        7.1.2 Bristol Myers Squibb Business Overview
        7.1.3 Bristol Myers Squibb Gestational Trophoblastic Disease Major Product Offerings
        7.1.4 Bristol Myers Squibb Gestational Trophoblastic Disease Revenue in Global Market (2018-2023)
        7.1.5 Bristol Myers Squibb Key News & Latest Developments
    7.2 Antares Pharma
        7.2.1 Antares Pharma Company Summary
        7.2.2 Antares Pharma Business Overview
        7.2.3 Antares Pharma Gestational Trophoblastic Disease Major Product Offerings
        7.2.4 Antares Pharma Gestational Trophoblastic Disease Revenue in Global Market (2018-2023)
        7.2.5 Antares Pharma Key News & Latest Developments
    7.3 Novartis AG
        7.3.1 Novartis AG Company Summary
        7.3.2 Novartis AG Business Overview
        7.3.3 Novartis AG Gestational Trophoblastic Disease Major Product Offerings
        7.3.4 Novartis AG Gestational Trophoblastic Disease Revenue in Global Market (2018-2023)
        7.3.5 Novartis AG Key News & Latest Developments
    7.4 Accord Healthcare Limited
        7.4.1 Accord Healthcare Limited Company Summary
        7.4.2 Accord Healthcare Limited Business Overview
        7.4.3 Accord Healthcare Limited Gestational Trophoblastic Disease Major Product Offerings
        7.4.4 Accord Healthcare Limited Gestational Trophoblastic Disease Revenue in Global Market (2018-2023)
        7.4.5 Accord Healthcare Limited Key News & Latest Developments
    7.5 Eli Lilly and Company
        7.5.1 Eli Lilly and Company Company Summary
        7.5.2 Eli Lilly and Company Business Overview
        7.5.3 Eli Lilly and Company Gestational Trophoblastic Disease Major Product Offerings
        7.5.4 Eli Lilly and Company Gestational Trophoblastic Disease Revenue in Global Market (2018-2023)
        7.5.5 Eli Lilly and Company Key News & Latest Developments
    7.6 Sanofi
        7.6.1 Sanofi Company Summary
        7.6.2 Sanofi Business Overview
        7.6.3 Sanofi Gestational Trophoblastic Disease Major Product Offerings
        7.6.4 Sanofi Gestational Trophoblastic Disease Revenue in Global Market (2018-2023)
        7.6.5 Sanofi Key News & Latest Developments
    7.7 Bayer AG
        7.7.1 Bayer AG Company Summary
        7.7.2 Bayer AG Business Overview
        7.7.3 Bayer AG Gestational Trophoblastic Disease Major Product Offerings
        7.7.4 Bayer AG Gestational Trophoblastic Disease Revenue in Global Market (2018-2023)
        7.7.5 Bayer AG Key News & Latest Developments
    7.8 Amgen
        7.8.1 Amgen Company Summary
        7.8.2 Amgen Business Overview
        7.8.3 Amgen Gestational Trophoblastic Disease Major Product Offerings
        7.8.4 Amgen Gestational Trophoblastic Disease Revenue in Global Market (2018-2023)
        7.8.5 Amgen Key News & Latest Developments
    7.9 Merck KGaA
        7.9.1 Merck KGaA Company Summary
        7.9.2 Merck KGaA Business Overview
        7.9.3 Merck KGaA Gestational Trophoblastic Disease Major Product Offerings
        7.9.4 Merck KGaA Gestational Trophoblastic Disease Revenue in Global Market (2018-2023)
        7.9.5 Merck KGaA Key News & Latest Developments
    7.10 Teva Pharmaceuticals
        7.10.1 Teva Pharmaceuticals Company Summary
        7.10.2 Teva Pharmaceuticals Business Overview
        7.10.3 Teva Pharmaceuticals Gestational Trophoblastic Disease Major Product Offerings
        7.10.4 Teva Pharmaceuticals Gestational Trophoblastic Disease Revenue in Global Market (2018-2023)
        7.10.5 Teva Pharmaceuticals Key News & Latest Developments
    7.11 B.P Pharma
        7.11.1 B.P Pharma Company Summary
        7.11.2 B.P Pharma Business Overview
        7.11.3 B.P Pharma Gestational Trophoblastic Disease Major Product Offerings
        7.11.4 B.P Pharma Gestational Trophoblastic Disease Revenue in Global Market (2018-2023)
        7.11.5 B.P Pharma Key News & Latest Developments
8 Conclusion
9 Appendix
    9.1 Note
    9.2 Examples of Clients
    9.3 Disclaimer

FAQ's

What does the report cover (Scope)?

It contains all the geographic trends, and market analysis for global market

ENTER REPORT NAME TO SEARCH

Gestational Trophoblastic Disease Market, Global Outlook and Forecast 2023-2029

Report Summary

Table of Contents

FAQ's

What does the report cover (Scope)?